What Is Tirzepatide? Benefits, Research & Safety
A first-in-class dual GLP-1 and GIP receptor agonist achieving unprecedented weight loss of up to 22% in clinical trials, approved for type 2 diabetes and obesity treatment.
UK summary: Licensed UK medicine (Mounjaro). Dual GLP-1 / GIP receptor agonist. Prescription-only. NHS access depends on NICE guidance and local commissioning. Counterfeit pens and unregulated 'research only' vials are a UK safety concern.
Quick Facts
Overview
Tirzepatide — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Licensed UK medicine (Mounjaro). Dual GLP-1 / GIP receptor agonist. Prescription-only. NHS access depends on NICE guidance and local commissioning. Counterfeit pens and unregulated 'research only' vials are a UK safety concern.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Mounjaro approved by MHRA for type 2 diabetes (2023). Zepbound for weight management under review/approved. Prescription-only medicine.
- EU: Mounjaro approved by EMA (September 2022) for type 2 diabetes. Weight management approval ongoing.
- Notes: Tirzepatide is a prescription-only medication. It is NOT a research peptide and should only be obtained through legitimate healthcare channels. Counterfeit products are a significant concern—only use verified pharmacies.
05Approved medical uses
- Mounjaro — UK weight management (NICE TA1026)
- Mounjaro — UK type 2 diabetes
06Unapproved / promotional claims
- Safe at any BMI without specialist input
- Compounded tirzepatide is equivalent to Mounjaro
- Best-in-class regardless of individual tolerability or comorbidities
07Common internet claims
- Up to 22% weight loss is a guarantee for everyone
- Skip the NHS waiting list — buy online instead
- Combine Mounjaro with research peptides for ‘maximum effect’
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Produces ~20% weight loss in eligible patients” | A | Yes | Low | SURMOUNT trials show mean weight loss in the high teens to low twenties (%) at maximum dose; individual results vary. |
| “Better than semaglutide for everyone” | B | Yes | Low | Head-to-head data suggest greater weight loss on average, but individual factors and side-effect tolerance matter — a prescriber decision. |
| “Generic 'tirzepatide' is the same as Mounjaro” | E | No | High | There is no licensed generic. 'Generic tirzepatide' is grey-market product without regulatory provenance. |
| “Compounded tirzepatide is a legal workaround” | E | No | High | UK compounding rules are narrow. Most 'compounded GLP-1' offers are not legitimate compounded medicine. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Nausea, vomiting, diarrhoea, constipation (common, dose-dependent)
- Gallbladder disease — class effect
- Pancreatitis — uncommon, recognised
- Hypoglycaemia in combination with insulin or sulfonylureas
- Contraindicated in pregnancy and breastfeeding
- February 2026 MHRA alert: falsified 15 mg KwikPens via unlicensed supply
11Drug-interaction uncertainty
Drug-interaction picture documented in the prescribing information.
12Anti-doping status
13UK legal position
Mounjaro approved by MHRA for type 2 diabetes (2023). Zepbound for weight management under review/approved. Prescription-only medicine.
14EU legal position
Mounjaro approved by EMA (September 2022) for type 2 diabetes. Weight management approval ongoing.
15What this page cannot tell you
- Whether tirzepatide is right for your individual clinical picture.
- Whether the pen you receive is genuine if obtained outside the regulated UK chain.
- How long you should stay on therapy — that is a prescriber decision.
- Whether NHS access in your region is currently open via primary care or only specialist services.
16Last reviewed
17Citation quality score
18Research gaps
- Long-term cardiovascular outcomes data continues to mature.
- Optimal management of weight regain after discontinuation.
- Safety / efficacy data in adolescents and older adults.
- Head-to-head data versus newer agents (retatrutide, CagriSema) when those mature.
19Safer alternatives / established care pathways
- Licensed Mounjaro or Wegovy via NHS specialist service or GMC-registered private prescriber.
- Structured weight-management programme as first-line.
- Bariatric assessment for patients meeting NICE criteria.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Am I eligible for NHS access to tirzepatide for my situation?
- What is the dose-titration plan and how will side effects be monitored?
- How do you confirm the product I receive is genuine Mounjaro?
- What is the plan if I want to come off the medicine?
- How should I report a suspected side effect?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Weight loss of 20-22% in clinical trials—approaching bariatric surgery results
- 2Superior glycaemic control with HbA1c reductions of 2.0-2.5%
- 3Significant reductions in liver fat (important for NAFLD/NASH)
- 4Improvements in blood pressure and lipid profiles
- 5High rates of diabetes remission (HbA1c <6.5% without medication)
- 6Reduced waist circumference and preferential visceral fat loss
- 7Improvements in markers of inflammation
- 8Better physical function and quality of life measures
- 9Potential cardiovascular benefits (outcomes trials ongoing)
Claim vs Evidence
How popular claims about Tirzepatide stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Produces ~20% weight loss in eligible patients” | A | Yes | Low | SURMOUNT trials show mean weight loss in the high teens to low twenties (%) at maximum dose; individual results vary. |
| “Better than semaglutide for everyone” | B | Yes | Low | Head-to-head data suggest greater weight loss on average, but individual factors and side-effect tolerance matter — a prescriber decision. |
| “Generic 'tirzepatide' is the same as Mounjaro” | E | No | High | There is no licensed generic. 'Generic tirzepatide' is grey-market product without regulatory provenance. |
| “Compounded tirzepatide is a legal workaround” | E | No | High | UK compounding rules are narrow. Most 'compounded GLP-1' offers are not legitimate compounded medicine. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Mounjaro/Zepbound: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg weekly |
| Frequency | Once weekly subcutaneous injection |
| Duration | Ongoing treatment; dose escalation over 20+ weeks |
| Notes | Tirzepatide is a prescription medication requiring medical supervision. Slow dose escalation is critical for tolerability. The highest doses (12.5mg, 15mg) are required for maximum weight loss but carry increased GI side effect risk. This is NOT a research peptide—obtain only through legitimate healthcare providers. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (Mounjaro, Zepbound)—once weekly
- Oral formulation in development
| Half-Life | Stability |
|---|---|
| Approximately 5 days (120 hours) | Refrigerate at 2-8°C before first use; can be kept at room temperature (below 30°C) for up to 21 days; protect from light |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Nausea (may be less severe than with pure GLP-1 agonists)
- Diarrhoea
- Vomiting
- Constipation
- Abdominal pain
- Decreased appetite
- Dyspepsia (indigestion)
- Injection site reactions
- Fatigue
- Hair loss (reported in weight loss trials—likely related to rapid weight loss)
Rare Risks & Concerns
- Pancreatitis
- Gallbladder disease and gallstones
- Hypoglycaemia (especially with insulin or sulfonylureas)
- Acute kidney injury (secondary to dehydration)
- Allergic reactions
- Thyroid C-cell tumours (rodent finding; clinical significance unknown)
- Intestinal obstruction (rare, in patients with GI disease)
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- Known hypersensitivity to tirzepatide
- Pregnancy and breastfeeding
- Type 1 diabetes
- History of pancreatitis
- Severe gastrointestinal disease
UK & EU Regulatory Context
🇬🇧 United Kingdom
Mounjaro approved by MHRA for type 2 diabetes (2023). Zepbound for weight management under review/approved. Prescription-only medicine.
🇪🇺 European Union
Mounjaro approved by EMA (September 2022) for type 2 diabetes. Weight management approval ongoing.
Clinical Studies Summary
SURMOUNT-1: Tirzepatide for Weight Management
Landmark obesity trial showing 15mg tirzepatide produced 22.5% mean weight loss vs 2.4% placebo over 72 weeks. 63% of participants lost ≥20% body weight.
SURPASS-2: Tirzepatide vs Semaglutide
Head-to-head comparison showing tirzepatide 15mg superior to semaglutide 1mg for glucose control (HbA1c reduction 2.46% vs 1.86%) and weight loss (12.4kg vs 6.2kg).
SURMOUNT-3: After Lifestyle Intervention
Tirzepatide after initial 12-week intensive lifestyle intervention showed total weight loss of 26.6% from pre-lifestyle baseline.
SURMOUNT-4: Weight Maintenance
Continuing tirzepatide after initial weight loss maintained weight reduction, while switching to placebo resulted in regain of approximately half the lost weight.
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.
Potent GLP-1 RAs, such as tirzepatide and semaglutide, demonstrate greater overall weight loss but are associated with a significant reduction in lean mass. None is related to this paper. CSM recused himself from handling this paper.
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.
In this systematic review and meta-analysis, discontinuing GLP-1RA treatment led to a pooled overall mean weight regain of 2.20 kg in participants taking liraglutide and 9.69 kg in those patients prescribed semaglutide/tirzepatide. The proportion of weight regained was proportional to the amount originally lost.
Registered Trials & Regulatory Status
21 of 66 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity
Status: Not Yet Recruiting · 40 participants · Royal North Shore Hospital
Conditions: Type 1 Diabetes Mellitus, Overweight and Obesity
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
Status: Not Yet Recruiting · 224 participants · Biomed Industries, Inc.
Conditions: Obesity and Overweight
Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF
Status: Not Yet Recruiting · 602 participants · Yunlong Wang
Conditions: Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFpEF), Tirzepatide
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants
Status: Not Yet Recruiting · 60 participants · Shanghai Zhongshan Hospital
Conditions: Obesity Adult Onset
Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer
Status: Not Yet Recruiting · 40 participants · UNC Lineberger Comprehensive Cancer Center
Conditions: Endometrial Cancer, Endometrial Intraepithelial Neoplasia, Grade 1 Endometrial Endometrioid Carcinoma
AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes
Status: Not Yet Recruiting · 285 participants · The First Affiliated Hospital of Anhui Medical University
Conditions: Obesity, Diabetes Mellitus, Type 2
Tirzepatide for the Treatment of Cannabis Use Disorder
Status: Not Yet Recruiting · 6 participants · Brigham and Women's Hospital
Conditions: Cannabis Use Disorder
Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery
Status: Not Yet Recruiting · 96 participants · Mario Musella MD
Conditions: Obesity (BMI > 35) and Diabetes Mellitus, Obesity (BMI > 35) and Dyslipemia, Obesity (BMI > 35) and High Blood Pressure
Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes
Status: Not Yet Recruiting · 44 participants · Victor Chang Cardiac Research Institute
Conditions: Type 1 Diabetes Mellitus
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
Status: Recruiting · 30 participants · Weill Medical College of Cornell University
Conditions: Obesity (Disorder), Breast Cancer
Incretin Therapies in Obesity-related HFpEF
Status: Not Yet Recruiting · 50 participants · Columbia University
Conditions: Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
Status: Recruiting · 204 participants · Regeneron Pharmaceuticals
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Adverse event reports (FDA FAERS)
- product tampering408
- nausea327
- vomiting279
- diarrhoea231
- fatigue132
- constipation130
- off label use120
- drug interaction104
- headache90
- drug ineffective88
FDA FAERS spontaneous reports. A report is not proof the substance caused the event, and an absence of reports is not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Tirzepatide?
Source research-grade Tirzepatide from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Tirzepatide
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Am I eligible for NHS access to tirzepatide for my situation?
- What is the dose-titration plan and how will side effects be monitored?
- How do you confirm the product I receive is genuine Mounjaro?
- What is the plan if I want to come off the medicine?
- How should I report a suspected side effect?
UK regulatory & safety context
Related Research Guides
Related Peptides
Semaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreLiraglutide
An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.
Learn moreGLP-1
A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
Learn moreRetatrutide
An investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, showing unprecedented weight loss of up to 24% in Phase 2 trials—potentially the most potent obesity treatment in development.
Learn more